Kristine Crews, PharmD

    Kristine R. Crews, PharmD

    Translational Research Laboratory Director
    Co-director, Pharmacokinetics Shared Resource
    Director, PGY2 Pharmacogenetics Residency Program
    Department of Pharmaceutical Sciences

    Contact Information

    Kristine R. Crews, PharmD, BCPS
    Pharmaceutical Sciences
    St. Jude Children's Research Hospital
    Mail Stop 313
    262 Danny Thomas Place
    Memphis, TN 38105-3678
    Phone: (901) 595-3338
    FAX: 901-595-8869


    BS - Rutgers, The State University of New Jersey, New Brunswick
    PharmD - Rutgers, The State University of New Jersey, New Brunswick
    Residency - Clinical Pharmacokinetics, University of Kentucky Medical Center, Lexington
    Fellowship - Clinical Pharmacokinetics/Pharmacodynamics and Drug Development, University of North Carolina School of Pharmacy, Chapel Hill and Glaxo Wellcome, Inc., Research Triangle Park, North Carolina

    Research Interests

    Selected Publications

    Stocco G, Crews KR. Pharmacogenetics, cost of genotyping and guidelines for individualizing therapy with mercaptopurine in pediatric acute lymphoblastic leukemia (letter). Pediatr Blood Cancer 2011. (Epub ahead of print Jul 27, 2011).

    Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE. Cancer pharmacogenomics. Clin Pharmacol Ther 90:461-6, 2011.

    Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011.

    Mitra AK, Crews KR, Pounds S, Cao X, Downing JR, Raimondi S, Campana D, Ribeiro RC, Rubnitz JE, Lamba JK. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia 25:1354-6, 2011.

    Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. J Pharmacol Exp Ther 339:9-23, 2011.

    McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville B, Navid F, Spunt SL, Santana VM, Furman WL, Rodriguez Galindo C. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer 2011. (Epub ahead of print April 20, 2011).

    Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamb V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12:327-39, 2011.

    Chen SH, Yang W, Fan Y, Stocco G, Crews KR, Yang JJ, Paugh SW, Pui CH, Evans WE, Relling MV. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 25:66-74, 2011.

    Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl transferase status. Expert Opin Drug Saf 9: 23-37, 2010.

    Inaba H, Stewart CF, Crews KR, Pounds S, Pui CH, Rubnitz JE, Razzouk BI, Ribeiro RC. Combination of cladribine plus topotecan for relapsed or refractory pediatric acute myeloid leukemia. Cancer 116:98-105, 2010.

    Crews KR, Zhou Y, Pauley J, Howard SC, Jeha S, Relling MV, Pui CH. Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer 116:227-32, 2010.

    Furman WL, Navid F, Daw NC, McCarville ME, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27:4599-604, 2009.

    Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi V, Raimondi SC, Downing JR, Razzouk BI, Pui CH, Ribeiro RC. Combination of Cladribine and Cytarabine is Effective for Childhood Acute Monoblastic Leukemia: Results of the St. Jude AML97 Trial. Leukemia 23:1410-6, 2009.

    Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz JE, Ribeiro RC, Downing JR, Lamba J. PROMISE: A tool to identify Genomic Features with a Specific Biologically Interesting Pattern of Correlations with Multiple Endpoint Variables. Bioinformatics 25:2013-9, 2009.

    Wagner LM, Villablanca JG, Stewart CF, Crews KR, O’Shaughnessy M, Groshen S, C. Patrick Reynolds CP, Park JR, Maris JM, Jackson HA, Matthay KK. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study.  J Clin Oncol 27: 1290-6, 2009.

    Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, Yang W, Cheng C, Pui CH, Relling MV, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences the metabolism of mercaptopurine and the risk of febrile neutropenia during treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 85:164-72, 2009.

    Yang JJ, Bhojwani D, Yang W, Cai X, Stocco G, Crews KR, Wang J, Morrison D, Devidas M, Hunger SP, Willman CL, Raetz EA, Pui CH, Evans WE, Relling MV, Carroll WL. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112: 4178-83, 2008.

    Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 19: 178-84, 2008.

    Wagner LM, Crews KR, Stewart CF, Rodriguez-Galindo C, McNall-Knapp RY, Albritton K, Pappo A, Furman WL. Reducing irinotecan-associated diarrhea in children. Ped Blood Cancer 50: 201-7, 2008.

    Lamba JK, Crews KR, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exper Ther 323: 935-45, 2007.

    Pappo AS, Lyden E, Breitfeld P, Donaldson S, Wiener E, Parham D, Crews KR, Houghton P, Meyer W. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 25: 362-9, 2007.

    Cheng Q, Cheng C, Crews KR, Ribeiro RC, Pui CH, Relling MV, Evans WE. Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Amer J Human Genet 79: 264-274, 2006.

    Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime allows greater dose-escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24: 563-570, 2006.

    Rodriguez-Galindo C, Crews KR, Stewart CF, Furman W, Panetta JP, Daw NC, Cain A, Tan M, Houghton PH, Santana VM. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 57: 15-24, 2006.

    Crews KR, Stewart CF, Liu T, Rodriguez-Galindo C, Santana VM, Daw NC. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hem/Onc 26: 764-7, 2004.

    Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100: 1724-33, 2004.

    Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, Goldsby RE, Albritton K, Stewart CF, Santana VM. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10: 840-8, 2004.

    Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CF, Crews KR. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 97 (9 Suppl):2374-80, 2003.

    Owens TS, Dodds H, Fricke K, Hanna SK, Crews KR. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. J Chromatogr B 788: 65-74, 2003.

    Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk BI. Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J Pediatr Hem/Onc 24: 677-680, 2002.

    Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 20:4217-4224, 2002.

    Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, and Gajjar A. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8:2202-9, 2002.

    Krance R, Hurwitz CA, Head DR, Raimondi SC, Behm FG, Crews KR, Srivastava DK, Mahmoud H, Roberts WM, Tong X, Blakley RL, Ribeiro RC. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 19:2804-11, 2001.